Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

Last updated: September 25, 2018
Sponsor: Wake Forest University Health Sciences
Overall Status: Terminated

Phase

1

Condition

Myocardial Ischemia

Emphysema

Angina

Treatment

N/A

Clinical Study ID

NCT00763035
IRB00006484
  • Ages 40-85
  • All Genders

Study Summary

The goal of this research is to determine the utility of Regadenoson (Lexiscan)for use as an imaging agent with cardiac MR. If found useful, it will help us establish a protocol for regadenoson stress MR perfusion (Regadenoson stress test with cardiac MR).The investigators will compare regadenoson with dobutamine so each participant will undergo two studies. A cardiac MR stress test with regadenoson and with dobutamine. The investigators participants will include patients with history of COPD and Asthma, so it will also help us determine feasibility of Regadenoson in these patient's subgroups.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men and women aged 40 to 85 years with OBSTRUCTIVE AIRWAY DISEASES (ASTHMA AND COPD)and a forced expiratory volume (FEV1) > 0.5.

  • Patients should have a clinical indication to undergo cardiac stress test withdobutamine.

Exclusion

Exclusion Criteria:

  • Those with pacemakers, defibrillators, functioning neural stimulator devices or otherimplanted electronic devices.

  • Ferromagnetic cerebral aneurism clips or other intraorbital and intracranial metal.

  • An allergy to Gadolinium or other severe drug allergies.

  • Acute myocardial infarction within 3 months.

  • Moderate or severe aortic stenosis or other significant valvular disease;

  • Claustrophobia.

  • High grade (2o or 3o) AV Block.

  • Closed angle glaucoma.

  • Participants unable to provide informed consent.

  • Renal dialysis (subjects with moderate-to-severe renal impairment defined as eGFR < 60mL/min.

  • A contraindication to receipt of dobutamine.

  • Participants with known coronary artery disease will be included with the exceptionthat patients with left main or narrowings >50% in the distributions of the leftanterior descending, circumflex, and right coronary artery will be excluded.

Study Design

Total Participants: 14
Study Start date:
January 01, 2009
Estimated Completion Date:
March 31, 2011

Connect with a study center

  • WAKE FOREST UNIVERSITY Baptist Medical Center

    Winston Salem, North Carolina 27157
    United States

    Site Not Available

  • WAKE FOREST UNIVERSITY Baptist Medical Center

    Winston-Salem, North Carolina 27157
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.